KR100997912B1 - 당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 - Google Patents
당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 Download PDFInfo
- Publication number
- KR100997912B1 KR100997912B1 KR1020080061463A KR20080061463A KR100997912B1 KR 100997912 B1 KR100997912 B1 KR 100997912B1 KR 1020080061463 A KR1020080061463 A KR 1020080061463A KR 20080061463 A KR20080061463 A KR 20080061463A KR 100997912 B1 KR100997912 B1 KR 100997912B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- layer fraction
- normal butanol
- ethyl acetate
- forget
- Prior art date
Links
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 23
- 206010012655 Diabetic complications Diseases 0.000 title claims abstract description 19
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title abstract description 13
- 239000000203 mixture Substances 0.000 title abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 144
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 120
- 239000000284 extract Substances 0.000 claims abstract description 114
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 86
- 241001442129 Myosotis Species 0.000 claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 claims abstract description 41
- 239000000047 product Substances 0.000 claims abstract description 41
- 230000036252 glycation Effects 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 229940093499 ethyl acetate Drugs 0.000 claims description 46
- 235000019439 ethyl acetate Nutrition 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims description 11
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 11
- 239000004459 forage Substances 0.000 claims description 7
- 206010007749 Cataract diabetic Diseases 0.000 claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 6
- 201000007025 diabetic cataract Diseases 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 26
- 102000016912 Aldehyde Reductase Human genes 0.000 abstract description 18
- 108010053754 Aldehyde reductase Proteins 0.000 abstract description 18
- 230000006872 improvement Effects 0.000 abstract description 7
- 230000003712 anti-aging effect Effects 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 230000009885 systemic effect Effects 0.000 abstract 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 21
- 238000004132 cross linking Methods 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 229930091371 Fructose Natural products 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229920005862 polyol Polymers 0.000 description 5
- 150000003077 polyols Chemical class 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 241000305599 Erigeron annuus Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940120624 myosotis arvensis extract Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HKNMYDUELTUXOL-UHFFFAOYSA-N 2,2,3-trimethylpentanedioic acid Chemical compound OC(=O)CC(C)C(C)(C)C(O)=O HKNMYDUELTUXOL-UHFFFAOYSA-N 0.000 description 2
- FWPVKDFOUXHOKQ-UHFFFAOYSA-N 2-[1-(carboxymethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)CCCC1 FWPVKDFOUXHOKQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001323 aldoses Chemical class 0.000 description 2
- -1 basement membrane Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010004903 glycosylated serum albumin Proteins 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical class O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- ZPKRBBYQFOQJRL-UHFFFAOYSA-N erigeroflavanone Natural products COC(=O)CC1(O)C(=O)C2=C(O)C=C(O)C=C2OC1(OC)C1=CC=C(O)C(O)=C1 ZPKRBBYQFOQJRL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000002232 fructoses Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- ZPKRBBYQFOQJRL-RBUKOAKNSA-N methyl 2-[(2r,3s)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2-methoxy-4-oxochromen-3-yl]acetate Chemical compound C1([C@@]2(OC)OC3=CC(O)=CC(O)=C3C(=O)[C@@]2(O)CC(=O)OC)=CC=C(O)C(O)=C1 ZPKRBBYQFOQJRL-RBUKOAKNSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002173 prosclerotic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
시 료 |
농도 (㎍/㎖) |
억제율(%) | IC50 (㎍/㎖) |
||||
14 days | 28 days |
14 days |
28 days |
14 days |
28 days |
||
개망초 전초의 추출물 |
2.5 5 50 |
2.5 10 25 |
11.48±1.28 12.59±1.70 59.26±1.70 |
0.77±1.49 7.62±1.07 65.52±0.66 |
40.95 | 20.90 | |
개망초 꽃 추출물 |
25 50 80 |
100 | 6.73±1.32 30.54±0.88 80.26±0.83 |
27.16±0.99 | 59.69 | 〉100 | |
개망초 꽃 추출물의 에칠아세테이트층 |
5 10 25 |
5 10 25 |
-8.51±0.74 7.47±1.82 79.92±0.37 |
-2.17±0.32 6.21±0.32 75.37±0.61 |
18.58 | 19.15 | |
개망초 꽃 추출물의 부탄올층 |
10 25 50 |
10 25 50 |
-7.51±1.01 27.86±0.88 78.65±0.76 |
2.51±0.62 21.48±0.36 63.34±0.49 |
36.26 | 41.94 | |
개망초 꽃 추출물의 헥산층 |
10 25 50 |
10 25 50 |
-23.10±1.36 -24.75±0.43 -24.67±0.76 |
-18.89±0.54 -12.99±0.54 -14.19±0.80 |
〉50 | 〉50 | |
개망초 꽃 추출물의 물층 |
10 25 50 |
10 25 50 |
-12.49±0.91 -12.93±0.91 -10.97±0.33 |
-8.34±0.55 -5.70±0.21 -12.77±0.70 |
〉50 | 〉50 | |
개망초 뿌리 추출물 |
12.5 50 75 |
10 25 50 |
5.59±0.44 25.15±0.92 51.26±0.63 |
-0.99±0.35 1.02±0.46 12.92±0.45 |
77.59 | 〉50 | |
개망초 뿌리 추출물의 에칠아세테이트층 |
2.5 5 10 |
5 10 25 |
8.21±1.09 20.26±0.44 69.17±0.11 |
-1.92±0.32 15.83±0.51 87.73±0.15 |
7.92 | 16.87 | |
개망초 뿌리 추출물의 부탄올 층 |
25 50 100 |
60 80 100 |
30.97±1.26 42.44±1.36 72.05±1.91 |
13.23±1.68 44.63±1.51 71.10±1.14 |
61.13 | 84.86 | |
개망초 뿌리 추출물의 헥산층 |
10 25 50 |
10 25 50 |
-6.31±0.84 -4.30±1.18 -5.41±0.62 |
-9.71±0.28 -10.29±0.37 -9.51±0.84 |
〉50 | 〉50 | |
개망초 뿌리 추출물의 물층 |
10 25 50 |
10 25 50 |
0.79±0.71 10.81±0.20 11.98±0.68 |
-5.88±0.19 -6.17±0.33 0.29±1.31 |
〉50 | 〉50 | |
개망초 줄기와 잎 추출물 |
10 25 50 |
60 80 100 |
7.79±0.49 28.07±0.25 68.36±0.49 |
21.59±3.35 45.71±2.15 66.03±1.12 |
38.35 | 84.92 | |
개망초 줄기와 잎 추출물의 에칠아세테이트층 |
2.5 5 10 |
5 10 25 |
9.60±0.25 31.41±0.76 81.59±0.22 |
2.61±0.54 27.00±0.35 87.67±0.17 |
6.78 | 15.93 | |
개망초 줄기와 잎 추출물의 부탄올층 |
10 25 50 |
60 80 100 |
-4.72±1.77 15.09±0.64 67.62±1.16 |
21.59±3.35 45.71±2.15 66.03±1.12 |
41.40 | 84.97 | |
개망초 줄기와 잎 추출물의 헥산층 |
10 25 50 |
10 25 50 |
-15.05±0.64 -19.34±0.51 -25.89±0.78 |
-10.42±0.07 -13.67±0.35 -13.07±0.41 |
〉50 | 〉50 | |
개망초 줄기와 잎 추출물의 물층 |
10 25 50 |
10 25 50 |
-2.17±0.33 2.43±0.69 1.60±1.28 |
-10.45±0.46 -13.10±0.07 -10.58±0.38 |
〉50 | 〉50 | |
Aminoguanidine(AG) | 18.5 55.5 74 |
18.5 37 92.5 |
12.70±6.12 39.46±1.91 50.68±0.51 |
14.89±4.11 24.93±3.46 50.41±0.41 |
72.12 | 91.30 |
시 료 |
농도 (㎍/㎖) |
억제율 (%) |
IC50 (㎍/㎖) |
개망초 전초 추출물 |
1.25 1.5 1.75 |
48.22±3.81 50.51±6.23 64.21±6.23 |
1.37 |
개망초 꽃 추출물 |
1.25 1.5 1.75 |
41.79±3.90 47.76±2.74 54.33±3.10 |
1.58 |
개망초 꽃 추출물의 헥산층 |
5 7.5 10 |
22.16±6.64 31.35±5.21 52.97±3.53 |
9.85 |
개망초 꽃 추출물의 에칠아세테이트층 |
1 2 3 |
40.76±11.46 69.75±7.04 71.97±8.56 |
1.31 |
개망초 꽃 추출물의 부탄올층 |
0.25 0.5 1 |
37.95±6.50 42.72±5.01 50.60±2.58 |
0.96 |
개망초 꽃 추출물의 물층 |
20 25 30 |
39.11±8.23 54.84±3.70 57.66±4.84 |
24.71 |
개망초 뿌리 추출물 |
0.5 0.75 1 |
31.77±4.37 43.48±8.35 51.84±3.48 |
0.94 |
개망초 뿌리 추출물의 헥산층 |
15 17.5 20 |
47.51±3.11 55.22±2.99 77.61±10.26 |
15.82 |
개망초 뿌리 추출물의 에칠아세테이트층 |
0.5 0.75 1 |
22.76±4.30 60.16±7.76 79.13±9.42 |
0.71 |
개망초 뿌리 추출물의 부탄올층 |
15 20 25 |
47.99±5.77 52.90±4.46 59.38±2.05 |
16.99 |
개망초 뿌리 추출물의 물층 |
40 | 5.80±10.14 | >40 |
개망초 줄기와 잎 추출물 |
1 2.5 5 |
37.25±9.44 50.2±6.48 73.73±2.45 |
2.43 |
개망초 줄기와 잎 추출물의 헥산층 |
5 7.5 10 |
35.51±8.54 42.51±0.42 62.80±9.06 |
8.06 |
개망초 줄기와 잎 추출물의 에칠아세테이트층 |
0.25 0.5 0.75 |
23.74±8.08 29.61±7.99 53.91±5.10 |
0.74 |
개망초 줄기와 잎 추출물의 부탄올층 |
0.75 1 1.25 |
42.19±3.91 65.10±5.20 69.01±1.80 |
0.84 |
개망초 줄기와 잎 추출물의 물층 |
15 20 25 |
38.89±8.40 45.41±5.53 62.56±4.66 |
20.44 |
Trimethylglutaric acid(TMG) |
3.72 5.59 7.45 |
31.42±5.71 56.42±9.60 69.69±8.15 |
5.34 (28.7 μM) |
Claims (8)
- 개망초의 전초, 또는 꽃, 또는 뿌리, 또는 줄기와 잎을 세절하여 알콜 또는 알콜 수용액으로 추출한 후, 추출된 추출액을 여과하고 감압 농축하여 얻어지는 개망초의 전초 또는 꽃 또는 뿌리 또는 줄기와 잎 추출물; 상기 개망초의 꽃 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 꽃 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물; 상기 개망초의 뿌리 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 뿌리 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물; 상기 개망초의 줄기와 잎 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 줄기와 잎 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물에 있어서,상기 개망초의 전초, 또는 꽃, 또는 뿌리, 또는 줄기와 잎의 추출물, 개망초의 꽃 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물, 개망초의 뿌리 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물, 개망초의 줄기와 잎 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물 중 어느 하나의 성분을 유효성분으로 함유하는, 최종당화산물 생성에 의해 유발되는 당뇨합병증의 예방 또는 치료용 약학적 조성물.
- 삭제
- 삭제
- 개망초의 전초, 또는 꽃, 또는 뿌리, 또는 줄기와 잎을 세절하여 알콜 또는 알콜 수용액으로 추출한 후, 추출된 추출액을 여과하고 감압 농축하여 얻어지는 개망초의 전초 또는 꽃 또는 뿌리 또는 줄기와 잎 추출물; 상기 개망초의 꽃 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 꽃 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물; 상기 개망초의 뿌리 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 뿌리 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물; 상기 개망초의 줄기와 잎 추출물을 헥산, 에칠아세테이트, 노르말 부탄올, 물 순으로 계통분리하여 에칠아세테이트 또는 노르말 부탄올로 분획되는 개망초의 줄기와 잎 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물에 있어서,상기 개망초의 전초, 또는 꽃, 또는 뿌리, 또는 줄기와 잎의 추출물, 개망초의 꽃 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물, 개망초의 뿌리 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물, 개망초의 줄기와 잎 추출물의 에칠아세테이트층 분획물 또는 노르말 부탄올층 분획물 중 어느 하나의 성분을 유효성분으로 함유하는, 최종당화산물 생성에 의해 유발되는 당뇨합병증 예방 및 개선용 건강기능식품.
- 삭제
- 삭제
- 제 1항에 있어서, 상기 최종당화산물 생성에 의해 유발되는 당뇨합병증은 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내장(diabetic cataract), 당뇨성 신증(diabetic nephropathy) 및 당뇨성 신경병증(diabetic neuropathy)으로 구성된 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 약학적 조성물.
- 제 4항에 있어서, 상기 최종당화산물 생성에 의해 유발되는 당뇨합병증은 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내장(diabetic cataract), 당뇨성 신증(diabetic nephropathy) 및 당뇨성 신경병증(diabetic neuropathy)으로 구성된 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 건강기능식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080061463A KR100997912B1 (ko) | 2008-06-27 | 2008-06-27 | 당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080061463A KR100997912B1 (ko) | 2008-06-27 | 2008-06-27 | 당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100001527A KR20100001527A (ko) | 2010-01-06 |
KR100997912B1 true KR100997912B1 (ko) | 2010-12-03 |
Family
ID=41811822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080061463A KR100997912B1 (ko) | 2008-06-27 | 2008-06-27 | 당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100997912B1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102086910B1 (ko) * | 2018-05-24 | 2020-03-09 | 산청군양잠농업협동조합 | 누에 혼합 환의 제조방법 및 상기 방법으로 제조된 누에 혼합 환 |
AU2019278986A1 (en) * | 2018-06-01 | 2020-12-10 | Yale University | Compositions and methods for treating steroid hormone-related diseases or disorders |
KR102193317B1 (ko) * | 2019-03-12 | 2020-12-22 | 주식회사 엔에스웰니스 | 비만 치료 및 개선용 조성물 |
KR102482510B1 (ko) * | 2022-07-18 | 2022-12-29 | 장순범 | 대마를 급여한 식용곤충을 이용한 건강식품 환의 제조방법 |
-
2008
- 2008-06-27 KR KR1020080061463A patent/KR100997912B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20100001527A (ko) | 2010-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100845469B1 (ko) | 벌개미취추출물 및 그를 유효성분으로 함유하는 약학적조성물 및 건강기능식품 | |
Abd El-Aal et al. | The effect of vitamin C and/or E supplementations on type 2 diabetic adult males under metformin treatment: A single-blinded randomized controlled clinical trial | |
Srinivasan et al. | Antidiabetic efficacy of citronellol, a citrus monoterpene by ameliorating the hepatic key enzymes of carbohydrate metabolism in streptozotocin-induced diabetic rats | |
Ananda et al. | Effect of Biophytum sensitivum on streptozotocin and nicotinamide-induced diabetic rats | |
Chandramohan et al. | Tyrosol, a phenolic compound, ameliorates hyperglycemia by regulating key enzymes of carbohydrate metabolism in streptozotocin induced diabetic rats | |
Peng et al. | Abelmoschus esculentus subfractions improved nephropathy with regulating dipeptidyl peptidase-4 and type 1 glucagon-like peptide receptor in type 2 diabetic rats | |
Baroni et al. | Hydroethanolic extract of Smallanthus sonchifolius leaves improves hyperglycemia of streptozotocin induced neonatal diabetic rats | |
US20090169648A1 (en) | Compositions to reduce blood glucose levels and treat diabetes | |
KR100997912B1 (ko) | 당뇨합병증 치료 및 예방용 약학적 조성물과 건강기능식품 | |
Buko et al. | Antidiabetic effects and erythrocyte stabilization by red cabbage extract in streptozotocin-treated rats | |
Xi et al. | Antioxidant and antiglycation properties of triterpenoid saponins from Aralia taibaiensis traditionally used for treating diabetes mellitus | |
Ramkumar et al. | Protective effect of Gymnema montanum against renal damage in experimental diabetic rats | |
Leme et al. | Role of prostaglandin/cAMP pathway in the diuretic and hypotensive effects of purified fraction of Maytenus ilicifolia Mart ex Reissek (Celastraceae) | |
Motto et al. | Antidiabetic and antioxidant potential of total extract and supernatant fraction of the roots of Anogeissus leiocarpus in HFD-fed and Streptozocin-induced diabetic rats | |
Aktaş et al. | Protective effects of rutin on acute lung injury induced by oleic acid in rats | |
Majidi et al. | Effects of Heracleum persicum hydroalcoholic extract on insulin, serum anti-oxidant enzymes, glucose, and lipid profiles in alloxan-induced diabetic rats | |
Chan et al. | Effects of fermented red bean extract on nephropathy in streptozocin-induced diabetic rats | |
De et al. | Antihyperglycemic and antihyperlipidemic effects of n-hexane fraction from the hydro-methanolic extract of sepals of Salmalia malabarica in streptozotocin-induced diabetic rats | |
Mostafa et al. | Inhibition of the hepatic glucose output is responsible for the hypoglycemic effect of Crataegus aronia against type 2 diabetes mellitus in rats | |
KR100973941B1 (ko) | 소석적려를 이용한 당뇨합병증 치료 및 예방용 조성물과기능성 식품 | |
da Silva et al. | Phenolic-rich extract of Nopalea cochenillifera attenuates gastric lesions induced in experimental models through inhibiting oxidative stress, modulating inflammatory markers and a cytoprotective effect | |
Packirisamy et al. | Antidiabetic effect of Coccinia grandis (L.) Voigt (Cucurbitales: Cucurbitaceae) on streptozotocin induced diabetic rats and its role in regulating carbohydrate metabolizing enzymes | |
Saha et al. | Antidiabetic and antioxidant activity of methanol extract of Ipomoea reptans Poir aerial parts in streptozotocin induced diabetic rats | |
KR100550934B1 (ko) | 후박추출물, 강후박추출물, 그로부터 분리한 마그놀올 및이들을 유효성분으로 포함하는 당뇨합병증 예방 또는치료용 약학적 조성물과 기능성 식품 | |
KR100951140B1 (ko) | 신규화합물 및 그를 유효성분으로 함유하는 당뇨합병증 치료 및 예방용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131001 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151030 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171123 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181029 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 10 |